Has Robyn Olney, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,496 in general payments to Robyn Olney, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robyn Olney, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robyn Olney, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robyn Olney, MD

Anatomic Pathology & Clinical Pathology · Dallas, TXNPI 1467642611

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (57.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Roche Molecular Systems, Inc. accounts for 74.8% of it on its own, with 2 other manufacturers making up the rest. Among anatomic pathology & clinical pathology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,496in general payments, 2019–2025

Across 6 payments — averaging $2249.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Roche Molecular Systems, Inc.$10K
Roche Diagnostics Corporation$3K
AstraZeneca$30

What the payments were for

Speaking & faculty fees$5,50241%
Travel & lodging$7,81358%
Food & beverage$1801%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Roche Molecular Systems, Inc.	2	$10,088
Roche Diagnostics Corporation	2	$3,377
AstraZeneca	2	$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

cobas Influenza A/B Nucleic acid test for use on the cobas Liat System$150

How this compares

$13,496 in reported general payments places this provider in the 95th percentile of 736 anatomic pathology & clinical pathology providers in Texas.

See all anatomic pathology & clinical pathology providers in Texas →

Medicare billing

Part B allowed, 2024

$8,393,214

Medicare patients

78,441

Services billed

758,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Dallas

Purva GopalDallas$11K
Mark PodberezinDallas$6K
Veena RajaramDallas$5K
Michael LeeDallas$3K
Wenxin ZhengDallas$3K
Cory RobertsDallas$3K
Carrie ChenaultDallas$2K
Christopher BibbBryan$1.1M
Rabia ShafiHouston$519K
Robert BradyFort Sam Houston$479K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →